An exploratory path model of the relationships between positive and negative adaptation to cancer on quality of life among non-Hodgkin lymphoma survivors.

Journal Article (Journal Article)

Adaptation is an ongoing, cognitive process with continuous appraisal of the cancer experience by the survivor. This exploratory study tested a path model examining the personal (demographic, disease, and psychosocial) characteristics associated with quality of life (QOL) and whether or not adaptation to living with cancer may mediate these effects. This study employed path analysis to estimate adaptation to cancer. A cross-sectional sample of NHL survivors (N = 750) was used to test the model. Eligible participants were ≥ 18 years, at least 2 years post-diagnosis, and living with or without active disease. Sixty-eight percent of the variance was accounted for in QOL. The strongest effect (-0.596) was direct by negative adaptation, approximately 3 times that of positive adaptation (0.193). The strongest demographic total effects on QOL were age and social support; <65 years of age had better QOL and better adaptation compared to those ≥ 65. Of the disease characteristics, comorbidity score had the strongest direct effect on QOL; each additional comorbidity was associated with a 0.309 standard deviation decline on QOL. There were no fully mediated effects through positive adaptation alone. Our exploratory findings support the coexistence of positive and negative adaptations perception as mediators of personal characteristics of the cancer experience. Negative adaptation can affect QOL in a positive way. Cancer survivorship is simultaneously shaped by both positive and negative adaptation with future research and implications for practice aimed at improving QOL.

Full Text

Duke Authors

Cited Authors

  • Bryant, AL; Smith, SK; Zimmer, C; Crandell, J; Jenerette, CM; Bailey, DE; Zimmerman, S; Mayer, DK

Published Date

  • May 2015

Published In

Volume / Issue

  • 33 / 3

Start / End Page

  • 310 - 331

PubMed ID

  • 25751114

Pubmed Central ID

  • PMC4455022

Electronic International Standard Serial Number (EISSN)

  • 1540-7586

International Standard Serial Number (ISSN)

  • 0734-7332

Digital Object Identifier (DOI)

  • 10.1080/07347332.2015.1020978


  • eng